



KEY HIGHLIGHTS

EVALUATE VANTAGE 2022 PREVIEW

What can we expect for the pharmaceutical and biotech sectors in 2022 and beyond?

Once again, the Evaluate Vantage Preview provides data-driven insights on best-sellers, potential blockbusters and upcoming regulatory developments, as well as trends in investment, venture financing, M&A activity and more.

OUT SOON - PREVIEW REPORT HIGHLIGHTS BELOW

TOP TEN PRODUCTS

Covid-19 vaccines from Pfizer and Moderna will be among biopharma's top-ten selling drugs next year.



NEW SALES: WHO WILL LEAD THE PACK?

AstraZeneca is expected to add the most new sales next year on a company level, driven by the Alexion acquisition and a strong performance from its oncology drugs.



POTENTIAL BLOCKBUSTERS

Three more Alzheimer's treatments could reach the market next year. Another approval to watch is Lilly's tirzepatide for diabetes and obesity.



Evaluate Vantage 2022 Preview

By Amy Brown, Edwin Eshelst and Joanne Fagg | DECEMBER 2021

Evaluate Vantage

Evaluate

ARE BIOPHARMA BUYOUTS PRIMED FOR A REBOUND?

Many are predicting an uptick in M&A next year, with buyers attracted by depressed valuations.



GOOD TIMES ROLL FOR VENTURE FINANCING

The venture capital sector is likely to have another strong year, with plenty of capital to deploy from well stocked funds.



IS IPO DEMAND DIMMING?

Biotechs could find it harder to IPO in the US next year, with investor appetite waning after a flood of early stage companies reached the market in the past 18 months.



REGISTER NOW

For priority access to the full Evaluate Vantage 2022 Preview Report.

Evaluate Vantage